Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H21N3O5S3 |
Molecular Weight | 383.507 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
InChI
InChIKey=HCRKCZRJWPKOAR-JTQLQIEISA-N
InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
Molecular Formula | C12H21N3O5S3 |
Molecular Weight | 383.507 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:12:39 UTC 2023
by
admin
on
Sat Dec 16 17:12:39 UTC 2023
|
Record UNII |
9451Z89515
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01EC54
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
NDF-RT |
N0000175517
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
NCI_THESAURUS |
C29577
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
SIMBRINZA (AUTHORIZED: GLAUCOMA, OPEN-ANGLE
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
AZARGA (AUTHORIZED: OCULAR HYPERTENSION)
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
NDF-RT |
N0000000235
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
AZOPT (AUTHORIZED: OCULAR HYPERTENSION)
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
SIMBRINZA (AUTHORIZED: OCULAR HYPERTENSION)
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
WHO-VATC |
QS01EC04
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
WHO-ATC |
S01EC04
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
AZARGA (AUTHORIZED: GLAUCOMA, OPEN-ANGLE)
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
NCI_THESAURUS |
C29705
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
AZOPT (AUTHORIZED: GLAUCOMA, OPEN-ANGLE)
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C47420
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
m2652
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
1076363
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
C111827
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
II-13
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL220491
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
7532
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
DTXSID6045531
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
68844
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
138890-62-7
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
6797
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
194881
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
3176
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
100000085244
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
760050
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
9451Z89515
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
SUB05892MIG
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
396
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
Brinzolamide
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
BRINZOLAMIDE
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
DB01194
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY | |||
|
9451Z89515
Created by
admin on Sat Dec 16 17:12:41 UTC 2023 , Edited by admin on Sat Dec 16 17:12:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
IC50 (CAII): 1.28 nM; IC50 (CAIV): 128 nM
BINDING
IC50
|
||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
International patent application: WO2013168186
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||